Evert Schimmelpennink

About Evert Schimmelpennink

Evert Schimmelpennink is a director at Contineum Therapeutics.

Form D filings name Evert Schimmelpennink as a president & CEO at Lenz Therapeutics and sits on its board.

Evert Schimmelpennink reports to the SEC as a director or officer of 4 public companies, including LENZ Therapeutics (LENZ), iBio (IBIO) and Pfenex (PFNX).

Evert Schimmelpennink first appears on SEC filings in 2017.

Experience

This experience comes from SEC filings. The years are when the filings name Evert Schimmelpennink in the role, so the role may have started earlier or lasted longer.

Key Colleagues at Startups

The people Evert Schimmelpennink works with at each company, as listed on that company's latest Form D.

Lenz Therapeutics, Inc. · Form D, Mar 10, 2023

JM

James McCollum

Director

CO

Clare Ozawa

Director

ZS

Zach Scheiner

Director

SL

Stefan Larson

Director

FG

Frederic Guerard

Director

Chris Dimitropoulos

Director

Sources

1. SECLenz Therapeutics, Inc. Form D, filed Mar 10, 2023
2. SECForms 3, 4 and 5 filed by Evert Schimmelpennink (SEC filer 1713795)